SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
Going to Scale With ART and PrEP
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
7 of
7
|
Themed Discussion Leader
Anne Cori
Imperial College London, London, United Kingdom
Effect of Eliminating CD4 Thresholds on Number of New ART Initiators in South Africa
Jacob Bor
Boston University School of Public Health, Boston, MA, United States
Optimizing Resource Allocation to Reduce HIV Incidence Across Sub-Saharan Africa
Jessica B. McGillen
Imperial College London, London, United Kingdom
New ARVs Could Represent More Than USD 3 Billion in Cost Savings Through 2025
Vineet R. Prabhu
Clinton Health Access Initiative, Boston, MA, United States
Impact of Improving HIV Care and Treatment and Initiating PrEP in the US, 2015-2020
Emine Yaylali
Centers for Disease Control and Prevention, Atlanta, GA, United States
PrEP Is Only Cost-Effective Among MSM in the Netherlands When Used on Demand
Brooke E. Nichols
Erasmus University Medical Center, Rotterdam, Netherlands
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
7 of
7
|
